Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/02/2024
• Auteurs : Hasnaa BenchorfiSébastien ChenuJ.-R. DuclèreCécile GenevoisMathieu AllixEmmanuel VéronJulie CornetteMaggy ColasV.A.G. RiveraVictor FuertesFrançois BrissetPierre CarlesSamar AoujiPhilippe ThomasYounes MessaddeqGaelle Delaizir
• Organismes : Université Laval [Québec] Institut de Recherche sur les CERamiques Institut des Sciences Chimiques de Rennes IRCER - Axe 3 : organisation structurale multiéchelle des matériaux IRCER - Axe 3 : organisation structurale multiéchelle des matériaux Conditions Extrêmes et Matériaux : Haute Température et Irradiation Conditions Extrêmes et Matériaux : Haute Température et Irradiation Conditions Extrêmes et Matériaux : Haute Température et Irradiation Institut de Recherche sur les CERamiques IRCER - Axe 3 : organisation structurale multiéchelle des matériaux Université Laval [Québec] Université Laval [Québec] Institut de Chimie Moléculaire et des Matériaux d'Orsay Institut de Recherche sur les CERamiques Université Laval [Québec] Institut de Chimie de la Matière Condensée de Bordeaux IRCER - Axe 3 : organisation structurale multiéchelle des matériaux Université Laval [Québec] IRCER - Axe 3 : organisation structurale multiéchelle des matériaux
• Publié dans Journal of the European Ceramic Society le 27/10/2020

---

Résumé : Glass samples belonging the TeO2 - Ta2O5 Bi2O3 (TTB) system are prepared by conventional melt-quenching technique and corresponding vitreous domain is identified. A crystallization study of 80 10 glass composition versus temperature shows structural transitions from to stabilization an unreported translucent anti-glass phase eventually a fully transparent crystalline ceramic in both visible infrared ranges. The structure microstructure phases characterized Powder X-Ray Diffraction, Electron Back-Scatter Transmission Microscopy Raman spectroscopy. optical properties undoped Er3+-doped also discussed. Up-conversion green emission band that intensity about 2 4 times more intense than ceramic, respectively. Furthermore, large spectral bandwidth 105 nm found sample. advantageous spectroscopic characteristics here, together with good thermal stability these samples, suggest has potential applications as amplification medium for generation ultrashort (femtoseconds) pulses.

---

Fichiers liés : Benchorfi et al-2023-Crystallization in the TeO2 - Ta2O5 - Bi2O3 system.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/02/2024
• Auteurs : Christian PfisterGwenaelle GravisAude FlechonChristine ChevreauHakim MahammediBrigitte LaguerreAline GuillotFlorence JolyMichel SoulieYves AlloryValentin HarterStéphane CulineGéraldine PignotJean Philippe FendlerLaurent GuyGrégory VerhoestNicolas MottetArnaud DoerflerSophie Abadie LacourtoisieAbde Rahmene AzzouziPierre MongiatLionnel GeoffroisPascal EschwègeFrédéric Di FioreGuilhem RoubaudJean Luc HoepffnerPhilippe BarthelemyHervé LangEric VoogEric MandronJean Marc TouraniCamille SerrateAlexandre ColauCarolina SaldanaAlexandre de la TailleThierry NguyenFrançois KleinclaussYohan LoriotJacques IraniJean Christophe EymardStéphane LarreOlivier HuillardMarc ZerbibFrédéric RollandJérôme RigaudNadine HouedeStéphane DroupyGeorgina MaloufMorgan RoupretSabine VieillotNicolas LetangTiffen LharidonNicolas GaschignardWerner HilgersJean Louis Davin
• Organismes : Hôpital Charles Nicolle [Rouen] Centre d'Investigation Clinique [CHU Rouen] Institut Paoli-Calmettes Centre de Recherche en Cancérologie de Marseille Département cancer environnement (Centre Léon Bérard - Lyon) IUCTO, ICR, TOULOUSE, France Centre Jean Perrin [Clermont-Ferrand] CRLCC Eugène Marquis Institut de Cancérologie de la Loire Lucien Neuwirth Centre Régional de Lutte contre le Cancer François Baclesse [Caen] Chirurgie Générale et Digestive [Rangueil] Institut Curie - Saint Cloud Centre Régional de Lutte contre le Cancer François Baclesse [Caen] Hopital Saint-Louis [AP-HP] Institut Paoli-Calmettes Service Urologie [CHU Clermont-ferrand] Centre Hospitalier Universitaire de Rennes [CHU Rennes] = Rennes University Hospital [Pontchaillou] Centre Hospitalier Régional Universitaire de Besançon Université de Bourgogne Service d'Urologie [CHU Caen] Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] Centre de Recherche en Automatique de Nancy CHU Rouen Université de Rouen Normandie Institut Bergonié [Bordeaux] Institut de Cancérologie de Strasbourg Europe Hôpitaux Universitaires de Strasbourg Clinique Victor Hugo [Le Mans] Université Gustave Eiffel - UFR Sciences humaines et sociales Groupe Hospitalier Diaconesses Croix Saint-Simon
• Publié dans Lancet Oncology le 02/11/2020

---

Résumé : Background: The optimal perioperative chemotherapy for patients with muscle-invasive bladder cancer is not defined. The VESPER (French Genito-Urinary Tumor Group and French Association of Urology V05) trial reported improved 3-year progression-free survival with dose-dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) versus gemcitabine and cisplatin (GC) in patients who received neoadjuvant therapy, but not in the overall perioperative setting. In this Article, we report on the secondary endpoints of overall survival and time to death due to bladder cancer at 5-year follow-up. Methods: VESPER was an open-label, randomised, phase 3 trial done at 28 university hospitals or comprehensive cancer centres in France, in which adults (age ≤18 years and ≤80 years) with primary bladder cancer and histologically confirmed muscle-invasive urothelial carcinoma were randomly allocated (1:1; block size four) to treatment with dd-MVAC (every 2 weeks for a total of six cycles) or GC (every 3 weeks for a total of four cycles). Overall survival and time to death due to bladder cancer (presented as 5-year cumulative incidence of death due to bladder cancer) was analysed by intention to treat (ITT) in all randomly assigned patients. Overall survival was assessed by the Kaplan-Meier method with the treatment groups compared with log-rank test stratified for mode of administration of chemotherapy (neoadjuvant or adjuvant) and lymph node involvement. Time to death due to bladder cancer was analysed with an Aalen model for competing risks and a Fine and Gray regression model stratified for the same two covariates. Results were presented for the total perioperative population and for the neoadjuvant and adjuvant subgroups. The trial is registered with ClinicalTrials.gov, NCT01812369, and is complete. Findings: From Feb 25, 2013, to March 1, 2018, 500 patients were randomly assigned, of whom 493 were included in the final ITT population (245 [50%] in the GC group and 248 [50%] in the dd-MVAC group; 408 [83%] male and 85 [17%] female). 437 (89%) patients received neoadjuvant chemotherapy. Median follow-up was 5·3 years (IQR 5·1-5·4); 190 deaths at the 5-year cutoff were reported. In the perioperative setting (total ITT population), we found no evidence of association of overall survival at 5 years with dd-MVAC treatment versus GC treatment (64% [95% CI 58-70] vs 56% [50-63], stratified hazard ratio [HRstrat] 0·79 [95% CI 0·59-1·05]). Time to death due to bladder cancer was increased in the dd-MVAC group compared with in the GC group (5-year cumulative incidence of death: 27% [95% CI 21-32] vs 40% [34-46], HRstrat 0·61 [95% CI 0·45-0·84]). In the neoadjuvant subgroup, overall survival at 5 years was improved in the dd-MVAC group versus the GC group (66% [95% CI 60-73] vs 57% [50-64], HR 0·71 [95% CI 0·52-0·97]), as was time to death due to bladder cancer (5-year cumulative incidence: 24% [18-30] vs 38% [32-45], HR 0·55 [0·39-0·78]). In the adjuvant subgroup, the results were not conclusive due to the small sample size. Bladder cancer progression was the cause of death for 157 (83%) of the 190 deaths; other causes of death included cardiovascular events (eight [4%] deaths), deaths related to chemotherapy toxicity (four [2%]), and secondary cancers (four [2%]). Interpretation: Our results on overall survival at 5 years were in accordance with the primary endpoint analysis (3-year progression-free survival). We found no evidence of improved overall survival with dd-MVAC over GC in the perioperative setting, but the data support the use of six cycles of dd-MVAC over four cycles of GC in the neoadjuvant setting. These results should impact practice and future trials of immunotherapy in bladder cancer.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/02/2024
• Auteurs : Mengjia WangPhilippe CiaisRasmus FensholtMartin BrandtShengli TaoWei LiLei FanFrédéric FrappartRui SunXiaojun LiXiangzhuo LiuHuan WangTianxiang CuiZanpin XingZhe ZhaoWigneron J.-P.
• Organismes : Zhengzhou University Laboratoire des Sciences du Climat et de l'Environnement [Gif-sur-Yvette] University of Copenhagen = Københavns Universitet University of Copenhagen = Københavns Universitet College of Urban and Environmental Sciences [Beijing] Tsinghua University [Beijing] Southwest University [Chongqing] Interactions Sol Plante Atmosphère Beijing Normal University Interactions Sol Plante Atmosphère Interactions Sol Plante Atmosphère Interactions Sol Plante Atmosphère Nanjing Forestry University Interactions Sol Plante Atmosphère Tsinghua University [Beijing] Interactions Sol Plante Atmosphère
• Publié dans Remote Sensing of Environment le 28/10/2020

---

Résumé : Vegetation dynamics in the African continent play an important role in the global terrestrial carbon cycle. Above-ground biomass carbon (AGC) stocks in Africa are sensitive to drought, fires and anthropogenic disturbances, and can be increased from forest restoration and tree plantation. However, there are large uncertainties in estimating changes that have occurred in AGC stocks in Africa over the past decades. Here, we used a microwave remote sensing-based vegetation index named Vegetation Optical Depth produced from X-band observations by INRAE Bordeaux (IB X-VOD) to describe the AGC dynamics in Africa covering recent decades. From 2003 to 2021, African AGC showed a net increase at a rate of +0.06 [+0.04, +0.07] PgC·yr−1 (the range represents the minimum and maximum AGC changes estimated by four calibrations), resulting from a large carbon gain of +0.55 [+0.46, +0.60] PgC·yr−1 during the first decade of the twenty-first century (period 1: 2003–2010) and a much weaker increase of +0.05 [+0.04, +0.07] PgC·yr−1 over the recent decade (period 2: 2013–2021). AGC gains were mainly found in non-forest woody areas, which contributed the most to the AGC changes during 2003–2021. Rainforests showed a minor AGC loss of −0.02 [−0.03, −0.02] PgC·yr−1, which emphasizes the need for forest conservation in Africa. Relationships between the AGC changes and potential forcing climate or anthropogenic variables suggested that human-induced deforestation and water stress (especially the vapor pressure deficit (VPD)) are the most important variables explaining the spatial and temporal AGC variations, respectively. For areas of rainforests, we identified a strong relationship between AGC and VPD (negative), soil moisture (positive) and radiation (positive). For areas of sparse vegetation (mainly located in drylands), AGC changes are largely dominated by changes in the soil water conditions. This study presents a new dataset for monitoring AGC dynamics at a continental scale over recent decades being independent of optical observations, quantifying the impacts of anthropogenic pressure and water stress on aboveground biomass carbon changes.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/02/2024
• Auteurs : Teddy NovaisSoraya QassemiPhilippe CestacCécile MccambridgeHélène VillarsBertrand DécaudinMathilde DambrineDominique Huvent-GrelleJean RocheDenis FedericoPierre Krolak-SalmonChristelle Mouchoux
• Organismes : Research on Healthcare Performance Centre Hospitalier Universitaire de Toulouse Pôle pharmacie [CHU Toulouse] Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps Pôle pharmacie [CHU Toulouse] Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps Pôle Gériatrie [CHU Toulouse] Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 Centre Hospitalier Régional Universitaire [CHU Lille] Centre Hospitalier Régional Universitaire [CHU Lille] Centre Hospitalier Régional Universitaire [CHU Lille] Hôpital des Charpennes [CHU - HCL] Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center
• Publié dans International Journal of Clinical Pharmacy le 23/10/2020

---

Résumé : Background: Patients with Alzheimer's disease and related dementias and their caregivers can be defined as people with higher risk of developing medication-related problems due to aging and polypharmacy. Aim: To assess the medication exposure of patient with Alzheimer's disease and related dementias and their caregivers. Method: Ancillary cross-sectional study based on baseline medication data of the PHARMAID RCT. The PHARMAID study was a multi-center RCT assessing an integrated pharmaceutical care at a psychosocial program. Older outpatients with Alzheimer's disease and related dementias and their older caregivers were eligible for inclusion. Baseline medication data were used to assess the medication exposure, illustrated by the number of medications, the prevalence of potentially inappropriate medications (PIMs) using the EU(7)-PIM list and the Medication Regimen Complexity Index (MRCI). Results: Seventy-three dyads were included in this ancillary study. The mean numbers (SD) of medications used by patients was 6.8 (2.6) and by caregivers was 4.7 (3.7). Overall, 60.3% of patients used at least one PIM and 47.9% of caregivers. Regarding the medication regimen complexity, the mean MRCI was 16.3(8.1) for patients and 11.3(10.5) for caregivers. Conclusion: The results of this study confirm the relevance of carrying out medication review with patients, but also with their caregivers who can be considered as hidden patients.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/02/2024
• Auteurs : Pierre GoudetGuillaume CadiotAnne BarlierEric BaudinFrançoise Borson-ChazotLaurent BrunaudRobert CaiazzoCatherine Cardot-BautersFrédéric CastinettiPhilippe ChansonThomas CunyEric DansinSébastien GaujouxSophie GiraudLionel GroussinMaëlle Le BrasJean-Christophe LifanteMuriel MathonnetLouis de MestierEric MiralliéFrançois PattouPauline RomanetFrédéric SebagChristophe TresalletDelphine VezzosiThomas WalterAntoine Tabarin
• Organismes : Recherche translationnelle sur le diabète - U 1190 Institut Cochin Recherche translationnelle sur le diabète - U 1190 Hospices Civils de Lyon Centre de Recherche en Cancérologie de Lyon Université Claude Bernard Lyon 1 Hôpital Edouard Herriot [CHU - HCL]
• Publié dans Annales d'Endocrinologie = Annals of Endocrinology le 25/10/2020

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/02/2024
• Auteurs : Geetika AggarwalJohn E MorleyBruno VellasAndrew D NguyenAndrew A ButlerSophie GuyonnetIsabelle CarriéLauréane BrigitteCatherine FaisantFrançoise LalaJulien DelrieuHélène VillarsEmeline CombrouzeCarole BadufleAudrey ZuerasSandrine AndrieuChristelle CantetChristophe MorinGabor Abellan van KanCharlotte DupuyYves RollandCéline CaillaudPierre-Jean OussetFrançoise LalaSherry WillisSylvie BellevilleBrigitte Gilbert-DussardierFrancine FontaineJean-François DartiguesIsabelle MarcetFleur DelvaAlexandra FoubertSandrine CerdaCorinne CostesOlivier RouaudPatrick ManckoundiaValérie QuipourtSophie MarilierEvelyne FranonLawrence BoriesMarie-Laure PaderMarie-France BassetBruno LapoujadeValérie FaureMichael Li Yung TongChristine Malick-LoiseauEvelyne Cazaban-CampistronFrançoise DesclauxColette BlatgeThierry DantoineCécile Laubarie-MouretIsabelle SaulnierJean-Pierre ClémentMarie-Agnès PicatLaurence Bernard-BourzeixStéphanie WilleboisIléana DésormaisNoëlle CardinaudMarc BonnefoyPierre LivetPascale RebaudetClaire GédéonCatherine BurdetFlavien TerracolAlain PesceStéphanie RothSylvie ChaillouSandrine LouchartKristel SudresNicolas LebrunNadège Barro-BelayguesJacques TouchonKarim BennysAudrey GabelleAurélia RomanoLynda TouatiCécilia MarelliCécile PaysPhilippe RobertFranck Le DuffClaire GervaisSébastien GonfrierYannick GasnierSerge BordesDanièle BegorreChristian CarpuatKhaled KhalesJean-François LefebvreSamira Misbah El IdrissiPierre SkolilJean-Pierre SallesCarole DufouilStéphane LehéricyMarie ChupinJean-François ManginAli BouhayiaMichèle AllardFrédéric RicolfiDominique DuboisMarie Paule Bonceour MartelFrançois CottonAlain BonaféStéphane ChanaletFrançoise HugonFabrice BonnevilleChristophe CognardFrançois CholletPierre PayouxThierry VoisinJulien DelrieuSophie PeifferAnne HitzelMichèle AllardMichel ZancaJacques MonteilJacques DarcourtLaurent MolinierHélène DerumeauxNadège CostaBertrand PerretClaire VinelSylvie Caspar-BauguilPascale Olivier-AbbalSandrine AndrieuChristelle CantetNicola Coley
• Organismes : Washington University School of Medicine [Saint Louis, MO] Washington University School of Medicine [Saint Louis, MO] Equipe AGING (CERPOP) Washington University School of Medicine [Saint Louis, MO] International Centre for Radio Astronomy Research Equipe AGING (CERPOP) Centre Hospitalier Universitaire de Toulouse Centre Hospitalier Universitaire de Toulouse Centre Hospitalier Universitaire de Toulouse Centre Hospitalier Universitaire de Toulouse Université Toulouse III - Paul Sabatier Equipe AGING (CERPOP) Pôle Gériatrie [CHU Toulouse] Equipe AGING (CERPOP) Centre de recherche en épidémiologie et santé des populations Centre Hospitalier Universitaire de Toulouse Equipe AGING (CERPOP) Centre Hospitalier Universitaire de Toulouse Laboratoire Eau Environnement et Systèmes Urbains Equipe AGING (CERPOP) Université Paris Descartes - École de sages-femmes Baudelocque Equipe AGING (CERPOP) Institut de Recherche sur les CERamiques Equipe AGING (CERPOP) Centre Hospitalier Universitaire de Toulouse University of Washington [Seattle] Centre de recherche de l'Institut universitaire de gériatrie de Montreal Centre de recherche de l'Institut universitaire de gériatrie de Montreal Bordeaux population health Bordeaux population health Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand CHU Dijon Service de médecine gériatrique (CHU de Dijon - Centre gériatrique de Champmaillot - EHPAD) Cabinet médical [Dijon] Equipe AGING (CERPOP) Université Toulouse III - Paul Sabatier Equipe AGING (CERPOP) Equipe EQUITY (CERPOP) Equipe EQUITY (CERPOP) Centre Hospitalier Universitaire de Toulouse Equipe AGING (CERPOP) Centre Hospitalier Universitaire de Toulouse Equipe AGING (CERPOP) Equipe AGING (CERPOP)
• Publié dans GeroScience le 30/10/2020

---

Résumé : The secreted peptide adropin is highly expressed in human brain tissues and correlates with RNA and proteomic risk indicators for dementia. Here we report that plasma adropin concentrations predict risk for cognitive decline in the Multidomain Alzheimer Preventive Trial (ClinicalTrials.gov Identifier, NCT00672685; mean age 75.8y, SD = 4.5 years, 60.2% female, n = 452). Cognitive ability was evaluated using a composite cognitive score (CCS) that assessed four domains: memory, language, executive function, and orientation. Relationships between plasma adropin concentrations and changes in CCS (∆CCS) were examined using Cox Proportional Hazards Regression, or by grouping into tertiles ranked low to high by adropin values and controlling for age, time between baseline and final visits, baseline CCS, and other risk factors (e.g., education, medication, APOE4 status). Risk of cognitive decline (defined as a ∆CCS of - 0.3 or more) decreased with increasing plasma adropin concentrations (hazard ratio = 0.873, 95% CI 0.780-0.977, P = 0.018). Between adropin tertiles, ∆CCS was significantly different (P = 0.01; estimated marginal mean ± SE for the 1st to 3rd tertile, - 0.317 ± 0.064; - 0.275 ± 0.063; - 0.042 ± 0.071; n = 133,146, and 130, respectively; P < 0.05 for 1st vs. 2nd and 3rd adropin tertiles). Normalized plasma Aß42/40 ratio and plasma neurofilament light chain, indicators of neurodegeneration, were significantly different between adropin tertile. These differences were consistent with reduced risk of cognitive decline with higher plasma adropin levels. Overall, these results suggest cognitive decline is reduced in community-dwelling older adults with higher circulating adropin levels. Further studies are needed to determine the underlying causes of the relationship and whether increasing adropin levels can delay cognitive decline.

---

Fichiers liés : s11357-023-00824-3.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/02/2024
• Auteurs : Boris AmoryClaire GoumardAlexis LaurentSerena LangellaDaniel CherquiEphrem SalaméLouise BarbierOlivier SoubraneOlivier FargesChristian HobeikaTakayuki KawaiJean-Marc RégimbeauFrançois FaitotPatrick PessauxStéphanie TruantEmmanuel BoleslawskiAstrid HerreroJean-Yves MabrutLaurence ChicheMarcello Di MartinoRami RhaiemLilian SchwarzVivian ResendeJulien CalderaroJérémy AugustinStefano CarusoDaniele SommacaleStefan HofmeyrAlessandro FerreroDavid FuksEric VibertGuido TorzilliOlivier ScattonRaffaele BrustiaJulio AbbaRené AdamMustapha AdhamPietro AddeoMarc-Antoine AllardGiuliana AmaddeoAhmet AyavDaniel AzoulayPhilippe BachellierPierre BalladurJulien BarbieuxEmmanuel BoleslawskiKarim BoudjemaM. BougardEmmanuel BucPetru O. BucurAntoine CarmeloFrançois CauchyDenis ChatelainJean ChauvatZineb CherkaouiMircea ChiricaOriana CiacioTatiana CodjiaFabio ColliLuciano de CarlisJean-Robert DelperoNicolas DemartinesOlivier DetryMarcelo Dias SanchesMomar DioufAlexandre DoussotChristian DucerfMehdi El AmraniJacques EwaldJean-Marc FabreHervé FagotSimone FamularoLéo FerreFrancesco FleresGilton Marques FonsecaÁlvaro Gancedo QuintanaBrice GayetAlessandro GiacomoniJean-Francois GigotNicolas GolseEmilie GregoireJean HardwigsenPaulo HermanThevi HorFrançois JehaesAli-Reza KianmaneshShohei KomatsuSophie LarocheChristophe LaurentYves-Patrice Le TreutPhilippe LeourierEmilie LermiteMikael LesurtelChristian LetoublonPaul LeymanMickael LesurtelJean LubranoJean-Yves MabrutGeorges MantionUgo MarcheseElena Martín-PérezBenjamin MenahemMaxime MeunierGuillaume Y. MilletKayvan MohkamAndré MulliriFabrice MuscariFrancis NavarroFrancisco NolascoTakeo NomiJean NunozGennaro NuzzoShinya OkumuraNassima OudafalGerard PascalGuillaume PassotDamiano PatronoFrançois PayeFabiano PerdigaoNiccolo PetruccianiGabriella PittauFrançois-René PruvotArtigas RaventosHélène RegnaultMichel RivoireRenato RomagnoliDidier RoulinAntonio Sa-CunhaMichel ScotteFrançois-Regis SoucheBertrand SucAlexandre ThobieBoris TrechotStéphanie TruantOlivier TuriniShinji UemotoXavier UnterteinerCharles VanbruggheJean Zemour
• Organismes : Centre de Recherche Saint-Antoine Service de chirurgie digestive Centre Hépato-Biliaire [Hôpital Paul Brousse] CHU Trousseau [Tours] Hôpital Haut-Lévêque - CHU de Bordeaux CHU Pitié-Salpêtrière [AP-HP] Institut Mutualiste de Montsouris Hôpital Beaujon [AP-HP] Service de chirurgie hepato-pancreato-biliaire Simplification des soins chez les patients complexes - UR UPJV 7518 Chirurgie digestive [CHU Amiens] Hôpital de Hautepierre [Strasbourg] Institute for Translational Medicine and Liver Disease Institut de Recherche sur les Maladies Virales et Hépatiques Service de chirurgie hepato-pancreato-biliaire Hôpital Claude Huriez [Lille] Hôpital Gui de Chauliac [CHU Montpellier] Hôpital de la Croix-Rousse [CHU - HCL] Hôpital Haut-Lévêque - CHU de Bordeaux Université Paris-Est Créteil Val-de-Marne - Faculté de médecine IMRB - VHC/"Viruses-Hepatology-Cancers" [Créteil] Simplification des soins chez les patients complexes - UR UPJV 7518 Direction de la recherche clinique et de l'innovation [CHU Amiens]
• Publié dans Surgery le 31/10/2020

---

Résumé : Background Combined hepatocholangiocarcinoma is a rare cancer with a grim prognosis composed of both hepatocellular carcinoma and intrahepatic cholangiocarcinoma morphologic patterns in the same tumor. The aim of this multicenter, international cohort study was to compare the oncologic outcomes after surgery of combined hepatocholangiocarcinoma to hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Methods Patients treated by surgery for combined hepatocholangiocarcinoma, hepatocellular carcinoma, and intrahepatic cholangiocarcinoma from 2000 to 2021 from multicenter international databases were analyzed retrospectively. Patients with combined hepatocholangiocarcinoma (cases) were compared with 2 control groups of hepatocellular carcinoma or intrahepatic cholangiocarcinoma, sequentially matched using a propensity score based on 8 preoperative characteristics. Overall and disease-free survival were compared, and predictors of mortality and recurrence were analyzed with Cox regression after propensity score matching. Results During the study period, 3,196 patients were included. Propensity score adjustment and 2 sequential matching processes produced a new cohort (n = 244) comprising 3 balanced groups was obtained (combined hepatocholangiocarcinoma = 56, intrahepatic cholangiocarcinoma = 66, and hepatocellular carcinoma = 122). Kaplan–Meier overall survival estimations at 1, 3, and 5 years were 67%, 45%, and 28% for combined hepatocholangiocarcinoma, 92%, 75%, and 55% for hepatocellular carcinoma, and 86%, 53%, and 42% for the intrahepatic cholangiocarcinoma group, respectively (P = .0014). Estimations of disease-free survival at 1, 3, and 5 years were 51%, 25%, and 17% for combined hepatocholangiocarcinoma, 63%, 35%, and 26% for the hepatocellular carcinoma group, and 51%, 31%, and 28% for the intrahepatic cholangiocarcinoma group, respectively (P = .19). Predictors of mortality were combined hepatocholangiocarcinoma subtype, metabolic syndrome, preoperative tumor markers alpha-fetoprotein and carbohydrate antigen 19-9, and satellite nodules, and recurrence was associated with satellite nodules rather than cancer subtype. Conclusion Despite data limitations, overall survival among patients with combined hepatocholangiocarcinoma was worse than both groups and closer intrahepatic cholangiocarcinoma, whereas disease-free survival was similar among the 3 groups. Future research on immunophenotypic profiling may hold more promise than traditional nonmodifiable clinical characteristics (as found in this study) in predicting recurrence or response to salvage treatments.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/02/2024
• Auteurs : Zhe ZhaoPhilippe CiaisWigneron J.-P.Maurizio SantoroMartin BrandtFritz KleinschrothSimon LewisJerome ChaveRasmus FensholtNadine LaporteDenis Jean SonwaSassan SaatchiLei FanHui YangXiaojun LiMengjia WangLei ZhuYidi XuJiaying HeWei Li
• Organismes : Tsinghua University [Beijing] Laboratoire des Sciences du Climat et de l'Environnement [Gif-sur-Yvette] Interactions Sol Plante Atmosphère Gamma Remote Sensing Research and Consulting AG IT University of Copenhagen Interactions Sol Plante Atmosphère
• Publié dans One Earth le 13/11/2020

---

Résumé : Disturbance, vegetation productivity, and recovery are crucial for aboveground biomass carbon (AGC) dynamics. Here, we use multiple satellite-based datasets to analyze the drivers of AGC dynamics in Central Africa. During 2010-2019, deforestation induced a gross AGC loss of 102.2 +/- 17.1 Tg C year- 1 , which was counterbalanced by an AGC increase of 116.9 +/- 41.1 Tg C year- 1 , leading to a net gain of 14.6 +/- 3.8 Tg C year- 1 . Compared to anthropogenic and soil factors, changes in climate-related factors (e.g., radiation) are more important for the non-deforestation AGC changes. A large AGC increase was found in the northern savannas. In moist forests, strong biomass recovery and growth largely compensated the carbon loss from deforestation and degradation. Considering the increasing resource demand due to rapid population growth, reconciling natural conservation and economic development in Central Africa remains challenging and depends on climate changes and country-specific social-economic conditions.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/02/2024
• Auteurs : Cordélia Salomez-IhlStéphane TanguyJean-Pierre AlcarazChloé DavinVictor Pascal-MoussellardMariem JabeurPierrick BedouchLudovic Le HegaratValérie FessardAnne-Louise BlierSylvie HuetPhilippe CinquinFrançois Boucher
• Organismes : Modélisation et Évaluation des données complexes en Santé Publique Modélisation et Évaluation des données complexes en Santé Publique
• Publié dans Mutation Research - Genetic Toxicology and Environmental Mutagenesis le 31/10/2020

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/02/2024
• Auteurs : Cordélia Salomez-IhlStéphane TanguyJean-Pierre AlcarazChloé DavinVictor Pascal-MoussellardMariem JabeurPierrick BedouchLudovic Le HegaratValérie FessardAnne-Louise BlierSylvie HuetPhilippe CinquinFrançois Boucher
• Organismes : Translational Innovation in Medicine and Complexity / Recherche Translationnelle et Innovation en Médecine et Complexité - UMR 5525 Centre Hospitalier Universitaire [CHU Grenoble] Physiologie cardio-Respiratoire Expérimentale Théorique et Appliquée Translational Innovation in Medicine and Complexity / Recherche Translationnelle et Innovation en Médecine et Complexité - UMR 5525 Translational Innovation in Medicine and Complexity / Recherche Translationnelle et Innovation en Médecine et Complexité - UMR 5525 Physiologie cardio-Respiratoire Expérimentale Théorique et Appliquée Translational Innovation in Medicine and Complexity / Recherche Translationnelle et Innovation en Médecine et Complexité - UMR 5525 Translational Innovation in Medicine and Complexity / Recherche Translationnelle et Innovation en Médecine et Complexité - UMR 5525 Centre Hospitalier Universitaire [CHU Grenoble] Laboratoire de Fougères - ANSES Laboratoire de Fougères - ANSES Laboratoire de Fougères - ANSES Laboratoire de Fougères - ANSES Translational Innovation in Medicine and Complexity / Recherche Translationnelle et Innovation en Médecine et Complexité - UMR 5525 Centre Hospitalier Universitaire [CHU Grenoble] Translational Innovation in Medicine and Complexity / Recherche Translationnelle et Innovation en Médecine et Complexité - UMR 5525
• Publié dans Mutation Research - Genetic Toxicology and Environmental Mutagenesis le 31/10/2020

---

Résumé : Preclinical and clinical studies have shown that molecular hydrogen (H2) has anti-oxidant, anti-inflammatory, and anti-apoptotic properties. Safety data are available in the literature and acute toxicity has been tested in isolated cells and laboratory animals. We have evaluates the genotoxicity of H2 in vivo in rats after 72 h exposure, following the International Council for Harmonization guidelines ICH S2 (R1). The study was conducted on three groups of male Wistar rats: a negative control group, a positive control group receiving methyl methanesulfonate, and a H2-treated group receiving a 3.1% H2 gas mixture for 72 h. Alkaline comet, formamidopyrimidine DNA glycosylase (Fpg)-modified comet and bone marrow micronucleus assays were performed. H2 exposure increased neither comet-tail DNA intensity (DNA damage) nor frequency of "hedgehogs" in blood, liver, lungs, or bronchoalveolar lavage fluid. No increase in Fpg-sensitive sites in lungs, no induction of micronucleus formation, and no imbalance of immature erythrocyte to total erythrocyte ratio (IME%) was observed in rats exposed to H2. The ICH S2 (R1) test-battery revealed no in vivo genotoxicity in Wistar rats after 72 h inhalation of a mixture containing 3.1% H2.

---

Source